Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 4/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL383413 | 0.98 | NNMT (0.70) | NNMTSMN1; SMN2EPHX2GRM5KDM4E | |
| Acetone SCHEMBL17558521 | 0.93 | NNMT (0.69) | NNMTSMN1; SMN2EPHX2GRM5KDM4E | |
| SCHEMBL20518762 | 0.87 | NNMT (0.57) | NNMTSMN1; SMN2EPHX2GRM5KDM4E | |
| Succinimide SCHEMBL28645192 | 0.85 | NNMT (0.55) | NNMTSMN1; SMN2EPHX2GRM5 | |
| SCHEMBL8722229 | 0.82 | NNMT (0.50) | NNMTKDM4EHCAR3 | |
| SCHEMBL29505896 | 0.82 | HCAR3 (0.67) | HCAR3 | |
| SCHEMBL18715409 | 0.82 | NNMT (0.70) | NNMTSMN1; SMN2EPHX2GRM5KDM4E | |
| SCHEMBL158601 | 0.82 | HCAR3 (0.67) | HCAR3 | |
| Succinimide SCHEMBL28224691 | 0.82 | NNMT (0.55) | NNMTSMN1; SMN2EPHX2HCAR3 | |
| SCHEMBL8815728 | 0.81 | NNMT (0.49) | NNMTHCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160083450-A1 | HUMAN PROTEIN SCAFFOLD WITH CONTROLLED SERUM PHARMACOKINETICS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-24 | — | — | US | disclosed |
| US-20120076728-A1 | HUMAN PROTEIN SCAFFOLD WITH CONTROLLED SERUM PHARMACOKINETICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-29 | — | — | US | disclosed |
| EP-2419120-A2 | HUMAN PROTEIN SCAFFOLD WITH CONTROLLED SERUM PHARMACOKINETICS | The Regents of the University of California (US) | 2012-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120076728-A1 | HUMAN PROTEIN SCAFFOLD WITH CONTROLLED SERUM PHARMACOKINETICS | ALB, SERPINA6, LGALS3BP | NNMT 4680/4885SMN1; SMN2 2018/4885EPHX2 4030/4885 |
| US-20160083450-A1 | HUMAN PROTEIN SCAFFOLD WITH CONTROLLED SERUM PHARMACOKINETICS | ALB, SERPINA6, LGALS3BP | NNMT 4680/4885SMN1; SMN2 2018/4885EPHX2 4030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.